Loading stock data…
$166.62+1.12 (+0.68%)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.
Glaukos Corporation in the Healthcare sector is trading at $166.62 with a market capitalization of $10.6B. Wall Street consensus targets $199.31 (13 analysts), implying a +19.6% move over the next 12 months. The stock is currently 13% below its 52-week high of $191.62, remaining 21.6% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $185.61M↑ | $150.57M↑ | $143.12M↑ | $133.54M↑ | $124.12M |
| Gross Profit | $151.59M↑ | $117.23M↑ | -$1.52M↓ | $104.71M↑ | $97.22M |
| Operating Income | -$15.77M↑ | -$19.86M↑ | -$139.87M↓ | -$16.36M↑ | -$22.69M |
| Net Income | -$18.38M↑ | -$19.78M↑ | -$133.66M↓ | -$16.23M↑ | -$19.66M |
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W...